Lowered circulating aspartate is a metabolic feature of human breast cancer

Guoxiang Xie, Bingsen Zhou, Aihua Zhao, Yunping Qiu, Xueqing Zhao, Lana Garmire, Yurii B. Shvetsov, Herbert Yu, Yun Yen, Wei Jia

研究成果: 雜誌貢獻文章

18 引文 (Scopus)

摘要

Distinct metabolic transformation is essential for cancer cells to sustain a high rate of proliferation and resist cell death signals. Such a metabolic transformation results in unique cellular metabolic phenotypes that are often reflected by distinct metabolite signatures in tumor tissues as well as circulating blood. Using a metabolomics platform, we find that breast cancer is associated with significantly (p = 6.27E-13) lowered plasma aspartate levels in a training group comprising 35 breast cancer patients and 35 controls. The result was validated with 103 plasma samples and 183 serum samples of two groups of primary breast cancer patients. Such a lowered aspartate level is specific to breast cancer as it has shown 0% sensitivity in serum from gastric (n = 114) and colorectal (n = 101) cancer patients. There was a significantly higher level of aspartate in breast cancer tissues (n = 20) than in adjacent non-tumor tissues, and in MCF-7 breast cancer cell line than in MCF-10A cell lines, suggesting that the depleted level of aspartate in blood of breast cancer patients is due to increased tumor aspartate utilization. Together, these findings suggest that lowed circulating aspartate is a key metabolic feature of human breast cancer.

原文英語
頁(從 - 到)33369-33381
頁數13
期刊Oncotarget
6
發行號32
DOIs
出版狀態已發佈 - 一月 1 2015

指紋

Aspartic Acid
Breast Neoplasms
Neoplasms
Cell Line
Metabolomics
Serum
Stomach
Cell Death
Phenotype

ASJC Scopus subject areas

  • Oncology

引用此文

Xie, G., Zhou, B., Zhao, A., Qiu, Y., Zhao, X., Garmire, L., ... Jia, W. (2015). Lowered circulating aspartate is a metabolic feature of human breast cancer. Oncotarget, 6(32), 33369-33381. https://doi.org/10.18632/oncotarget.5409

Lowered circulating aspartate is a metabolic feature of human breast cancer. / Xie, Guoxiang; Zhou, Bingsen; Zhao, Aihua; Qiu, Yunping; Zhao, Xueqing; Garmire, Lana; Shvetsov, Yurii B.; Yu, Herbert; Yen, Yun; Jia, Wei.

於: Oncotarget, 卷 6, 編號 32, 01.01.2015, p. 33369-33381.

研究成果: 雜誌貢獻文章

Xie, G, Zhou, B, Zhao, A, Qiu, Y, Zhao, X, Garmire, L, Shvetsov, YB, Yu, H, Yen, Y & Jia, W 2015, 'Lowered circulating aspartate is a metabolic feature of human breast cancer', Oncotarget, 卷 6, 編號 32, 頁 33369-33381. https://doi.org/10.18632/oncotarget.5409
Xie G, Zhou B, Zhao A, Qiu Y, Zhao X, Garmire L 等. Lowered circulating aspartate is a metabolic feature of human breast cancer. Oncotarget. 2015 1月 1;6(32):33369-33381. https://doi.org/10.18632/oncotarget.5409
Xie, Guoxiang ; Zhou, Bingsen ; Zhao, Aihua ; Qiu, Yunping ; Zhao, Xueqing ; Garmire, Lana ; Shvetsov, Yurii B. ; Yu, Herbert ; Yen, Yun ; Jia, Wei. / Lowered circulating aspartate is a metabolic feature of human breast cancer. 於: Oncotarget. 2015 ; 卷 6, 編號 32. 頁 33369-33381.
@article{ac153d7b5b2044fd98cca606aff5bff4,
title = "Lowered circulating aspartate is a metabolic feature of human breast cancer",
abstract = "Distinct metabolic transformation is essential for cancer cells to sustain a high rate of proliferation and resist cell death signals. Such a metabolic transformation results in unique cellular metabolic phenotypes that are often reflected by distinct metabolite signatures in tumor tissues as well as circulating blood. Using a metabolomics platform, we find that breast cancer is associated with significantly (p = 6.27E-13) lowered plasma aspartate levels in a training group comprising 35 breast cancer patients and 35 controls. The result was validated with 103 plasma samples and 183 serum samples of two groups of primary breast cancer patients. Such a lowered aspartate level is specific to breast cancer as it has shown 0{\%} sensitivity in serum from gastric (n = 114) and colorectal (n = 101) cancer patients. There was a significantly higher level of aspartate in breast cancer tissues (n = 20) than in adjacent non-tumor tissues, and in MCF-7 breast cancer cell line than in MCF-10A cell lines, suggesting that the depleted level of aspartate in blood of breast cancer patients is due to increased tumor aspartate utilization. Together, these findings suggest that lowed circulating aspartate is a key metabolic feature of human breast cancer.",
keywords = "Aspartate, Breast cancer, Diagnosis, Metabolomics, Multivariate analysis",
author = "Guoxiang Xie and Bingsen Zhou and Aihua Zhao and Yunping Qiu and Xueqing Zhao and Lana Garmire and Shvetsov, {Yurii B.} and Herbert Yu and Yun Yen and Wei Jia",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5409",
language = "English",
volume = "6",
pages = "33369--33381",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "32",

}

TY - JOUR

T1 - Lowered circulating aspartate is a metabolic feature of human breast cancer

AU - Xie, Guoxiang

AU - Zhou, Bingsen

AU - Zhao, Aihua

AU - Qiu, Yunping

AU - Zhao, Xueqing

AU - Garmire, Lana

AU - Shvetsov, Yurii B.

AU - Yu, Herbert

AU - Yen, Yun

AU - Jia, Wei

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Distinct metabolic transformation is essential for cancer cells to sustain a high rate of proliferation and resist cell death signals. Such a metabolic transformation results in unique cellular metabolic phenotypes that are often reflected by distinct metabolite signatures in tumor tissues as well as circulating blood. Using a metabolomics platform, we find that breast cancer is associated with significantly (p = 6.27E-13) lowered plasma aspartate levels in a training group comprising 35 breast cancer patients and 35 controls. The result was validated with 103 plasma samples and 183 serum samples of two groups of primary breast cancer patients. Such a lowered aspartate level is specific to breast cancer as it has shown 0% sensitivity in serum from gastric (n = 114) and colorectal (n = 101) cancer patients. There was a significantly higher level of aspartate in breast cancer tissues (n = 20) than in adjacent non-tumor tissues, and in MCF-7 breast cancer cell line than in MCF-10A cell lines, suggesting that the depleted level of aspartate in blood of breast cancer patients is due to increased tumor aspartate utilization. Together, these findings suggest that lowed circulating aspartate is a key metabolic feature of human breast cancer.

AB - Distinct metabolic transformation is essential for cancer cells to sustain a high rate of proliferation and resist cell death signals. Such a metabolic transformation results in unique cellular metabolic phenotypes that are often reflected by distinct metabolite signatures in tumor tissues as well as circulating blood. Using a metabolomics platform, we find that breast cancer is associated with significantly (p = 6.27E-13) lowered plasma aspartate levels in a training group comprising 35 breast cancer patients and 35 controls. The result was validated with 103 plasma samples and 183 serum samples of two groups of primary breast cancer patients. Such a lowered aspartate level is specific to breast cancer as it has shown 0% sensitivity in serum from gastric (n = 114) and colorectal (n = 101) cancer patients. There was a significantly higher level of aspartate in breast cancer tissues (n = 20) than in adjacent non-tumor tissues, and in MCF-7 breast cancer cell line than in MCF-10A cell lines, suggesting that the depleted level of aspartate in blood of breast cancer patients is due to increased tumor aspartate utilization. Together, these findings suggest that lowed circulating aspartate is a key metabolic feature of human breast cancer.

KW - Aspartate

KW - Breast cancer

KW - Diagnosis

KW - Metabolomics

KW - Multivariate analysis

UR - http://www.scopus.com/inward/record.url?scp=84946069241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946069241&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5409

DO - 10.18632/oncotarget.5409

M3 - Article

VL - 6

SP - 33369

EP - 33381

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -